Ontology highlight
ABSTRACT: Introduction
Treatment with topotecan is standard-of-care therapy for relapsed small-cell lung cancer (SCLC). Both oral and intravenous administrations of topotecan have been extensively researched and are found to be equally effective with less adverse events in the oral group.Case presentation
We report a case of a patient with SCLC, who had previously received oral topotecan, with radiological stable disease with no changes in tumor or metastasis diameter size after two administrations. Subsequently, this patient received intravenous topotecan instead of oral due to supply difficulties. After one administration of intravenous topotecan, we saw significant disease regression.Conclusion
This is to our knowledge the first reported case of better response of intraven
SUBMITTER: Deraedt D
PROVIDER: S-EPMC11521484 | biostudies-literature | 2024 Jan-Dec
REPOSITORIES: biostudies-literature